Related references
Note: Only part of the references are listed.Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas
Isabelle Ray-Coquard et al.
CANCER RESEARCH (2009)
Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer
Daniel J. Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Is there a difference in survival between right- versus left-sided colon cancers?
Robert A. Meguid et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies
Imke Atreya et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Surrogate end points for median overall survival in metastatic colorectal cancer: Literature-based analysis from 39 Randomized controlled trials of first-line chemotherapy
Patricia A. Tang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study
J. Alexandre et al.
ANNALS OF ONCOLOGY (2007)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells
SA Rosenberg et al.
JOURNAL OF IMMUNOTHERAPY (2006)
Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention
TL Whiteside
SEMINARS IN CANCER BIOLOGY (2006)
Effector memory T cells, early metastasis, and survival in colorectal cancer
F Pagès et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+ CD25+ regulatory T cells
H Zhang et al.
NATURE MEDICINE (2005)
Drug therapy - Systemic therapy for colorectal cancer
JA Meyerhardt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer
C Borg et al.
CANCER (2004)
Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials
E Mitry et al.
ANNALS OF ONCOLOGY (2004)
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
T Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy
I Ray-Coquard et al.
BRITISH JOURNAL OF CANCER (2003)
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer:: results of a multivariate analysis of 3825 patients
CH Köhne et al.
ANNALS OF ONCOLOGY (2002)
Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas
I Ray-Coquard et al.
BRITISH JOURNAL OF CANCER (2001)
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
V Shankaran et al.
NATURE (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer
FGA Jansman et al.
DRUG SAFETY (2000)
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure
G. Freyer et al.
BRITISH JOURNAL OF CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
